First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Carbone, David P; Reck, Martin; Paz-Ares, Luis; Creelan, Benjamin; Horn, Leora; Steins, Martin; Felip, Enriqueta; van den Heuvel, Michel M; Ciuleanu, Tudor-Eliade; Badin, Firas; Ready, Neal; Hiltermann, T Jeroen N; Nair, Suresh; Juergens, Rosalyn; Peters, Solange; Minenza, Elisa; Wrangle, John M; Rodriguez-Abreu, Delvys; Borghaei, Hossein; Blumenschein, George R; Villaruz, Liza C; Havel, Libor; Krejci, Jana; Corral Jaime, Jesus; Chang, Han; Geese, William J; Bhagavatheeswaran, Prabhu; Chen, Allen C; Socinski, Mark A; Vansteenkiste, Johan

doi:10.1056/NEJMoa1613493

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Author:

Carbone, David P

Reck, Martin ; Paz-Ares, Luis ; Creelan, Benjamin ; Horn, Leora ; Steins, Martin ; Felip, Enriqueta ; van den Heuvel, Michel M ; Ciuleanu, Tudor-Eliade ; Badin, Firas ; Ready, Neal ; Hiltermann, T Jeroen N ; Nair, Suresh ; Juergens, Rosalyn ; Peters, Solange ; Minenza, Elisa ; Wrangle, John M ; Rodriguez-Abreu, Delvys ; Borghaei, Hossein ; Blumenschein, George R ; Villaruz, Liza C ; Havel, Libor ; Krejci, Jana ; Corral Jaime, Jesus ; Chang, Han ; Geese, William J ; Bhagavatheeswaran, Prabhu ; Chen, Allen C ; Socinski, Mark A ; Vansteenkiste, Johan

Keywords:

Antigens, CD274, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Humans, Lung Neoplasms, B7-H1 Antigen, CheckMate 026 Investigators, 11 Medical and Health Sciences, General & Internal Medicine, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.